Beam Therapeutics Inc
NASDAQ:BEAM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.22
45.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beam Therapeutics Inc
Wall Street
Price Targets
BEAM Price Targets Summary
Beam Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
BEAM
is 50.27 USD
with a low forecast of 23.23 USD and a high forecast of 84 USD.
BEAM Last Price Targets
Beam Therapeutics Inc
The latest public price target was made on Nov 6, 2024 by
Rick Bienkowski
from
Leerink Partners
,
who expects
BEAM
stock to
rise by 34%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Rick Bienkowski
Leerink Partners
|
39
USD
Upside 34% |
1 month ago
Nov 6, 2024
|
Leerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'
StreetInsider
|
Kostas Biliouris
BMO Capital
|
57
USD
Upside 96% |
1 month ago
Nov 5, 2024
|
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
StreetInsider
|
Benjamin Burnett
Stifel Nicolaus
|
69
USD
Upside 138% |
3 months ago
Sep 11, 2024
|
Beam Therapeutics Inc (BEAM) PT Raised to $69 at Stifel
StreetInsider
|
|
Unknown Analyst
Cantor Fitzgerald
|
62
USD
Upside 114% |
1 year ago
Feb 1, 2023
|
Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BEAM's stock price target?
Price Target
50.27
USD
According to Wall Street analysts, the average 1-year price target for
BEAM
is 50.27 USD
with a low forecast of 23.23 USD and a high forecast of 84 USD.
What is Beam Therapeutics Inc's Revenue forecast?
Projected CAGR
-33%
The
compound annual growth rate
of Beam Therapeutics Inc's revenue for the next 4 years is
-33%.
You don't have any saved screeners yet
